Group 1 - The core point of the article is the strategic cooperation agreement signed between Yatani Group and Guangzhou Baiyunshan Weiyi Industrial Co., Ltd. to jointly develop products in the health sector and expand market reach [1][2] Group 2 - The strategic cooperation agreement is set for a duration of one year and focuses on joint product development in areas such as natural plant extracts, functional health products, and personal care products [1] - The collaboration aims to leverage Baiyunshan Weiyi's brand marketing support, including brand strategy, trademark licensing, and technical consulting for sales and market promotion [1] - This partnership aligns with the company's strategy to expand its beauty and health product sales, enhancing its core competitiveness in the health sector and opening new revenue streams [2]

Core Viewpoint - The strategic cooperation agreement between Yatani Group and Guangzhou Baiyunshan Weiyi Industrial Co., Ltd. aims to jointly develop products in the health sector and expand market reach, with a focus on innovation and international marketing support [1][2]. Group 1: Strategic Cooperation Details - The cooperation agreement is set for one year, focusing on joint research and development of products in the health sector, including natural plant extracts, functional health products, and personal care items [1]. - Baiyunshan Weiyi will provide brand marketing support, including brand strategy, trademark licensing, and technical consulting for sales and market promotion related to health products [1]. Group 2: Business Development Strategy - The partnership aligns with the company's strategy to expand its beauty and health product sales, enhancing its long-term positioning in the health industry [2]. - The board believes that this collaboration will leverage the company's international market advantages and Baiyunshan Weiyi's technical and brand strengths, creating synergies that could enrich the product portfolio and open new revenue streams [2].

Group 1 - The top three companies by Hong Kong Stock Connect holding ratios are China Telecom (00728) at 71.84%, Green Power Environmental (01330) at 69.15%, and China Shenhua (01088) at 68.07% [1] - The latest holding ratio rankings for the top 20 companies show significant ownership levels, with companies like Kaisa New Energy (01108) and COSCO Shipping Energy (01138) also exceeding 67% [1] - The recent five trading days saw Alibaba-W (09988) leading in increased holdings with a rise of 143.50 billion, followed by Yingfu Fund (02800) with an increase of 41.59 billion [1][2] Group 2 - The companies with the largest decreases in holdings over the last five trading days include Meituan-W (03690) with a reduction of 12.14 billion, Great Wall Motors (02333) with a decrease of 8.01 billion, and Xiaomi Group-W (01810) with a drop of 7.57 billion [2] - Other notable companies experiencing significant reductions in holdings include Tencent Holdings (00700) and Li Auto-W (02015), with decreases of 4.65 billion and 4.06 billion respectively [2] - The data reflects a dynamic trading environment, with substantial shifts in investor sentiment towards various companies within the Hong Kong market [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 中國廣州，2025年9月17日 於本公告日，本公司董事會成員包括執行董事李小軍先生、程寧女士、程洪進先生、唐和平先生與 黎洪先生，及獨立非執行董事陳亞進先生、黃民先生、黃龍德先生與孫寶清女士。 白云山 2025 年第二次临时股东大会 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出的。 茲刊載廣州白雲山醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(www.sse.com.cn)刊登的 本公司2025年第二次臨時股東大會會議資料之中文全文，僅供參考。 廣州白雲山醫藥集團股份有限公司 董事會 广州白云山医药集团股份有限公司 2025 年第二次临时股东大会会议资料 2025 年 9 月 26 日 第 1 页 共 141 页 白云山 2025 年第二次临时股东大会 目 录 | 一、会议须知……………………………………………………3 | | --- | | 二、会议议程 ...

白云山 2025 年第二次临时股东大会 广州白云山医药集团股份有限公司 2025 年第二次临时股东大会会议资料 2025 年 9 月 26 日 第 1 页 共 141 页 白云山 2025 年第二次临时股东大会 目 录 | 一、会议须知……………………………………………………3 | | --- | | 二、会议议程……………………………………………………5 | | 三、会议议案……………………………………………………6 | 第 2 页 共 141 页 白云山 2025 年第二次临时股东大会 广州白云山医药集团股份有限公司 2025 年第二次临时股东大会会议须知 为了维护广州白云山医药集团股份有限公司（以下简称"本公司"或"公司"） 全体股东的合法权益，确保本公司 2025 年第二次临时股东大会（以下简称"临 时股东大会"或"本次临时股东大会"）正常秩序和议事效率，保证临时股东大 会的顺利进行，依据有关法律法规、《广州白云山医药集团股份有限公司章程》 （以下简称"《公司章程》"）及《广州白云山医药集团股份有限公司股东大 会议事规则》（以下简称"《股东大会议事规则》"）的有关规定，特制订本 须知。 一、本次临时股 ...

Core Viewpoint - Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. has received approval for supplementary applications for several drugs, enhancing their safety information and specifications, which is expected to improve market competitiveness [1][17]. Drug Information 1. Abukuan Tablets - Generic Name: Abukuan Tablets - Dosage Form: Tablets - Specification: Each tablet weighs 0.25g (equivalent to 3.33g of raw material) - Approval Notification Number: 2025B03040 - Application Content: Changes to safety information in the drug instructions and specifications [1][8]. - Market Sales: In 2024, the domestic sales amounted to RMB 27.74 million, with Baiyunshan's sales at RMB 6.3754 million [9]. 2. Kunling Pills - Generic Name: Kunling Pills - Dosage Form: Pills (Concentrated Pills) - Specification: Each 10 pills weigh 2.7g (equivalent to 2.6g of raw material) - Approval Notification Number: 2025B03908 - Application Content: Changes to safety information in the drug instructions [2][11]. - Market Sales: In 2024, the domestic sales amounted to RMB 13.15 million, with no sales recorded for Baiyunshan [11]. 3. Shenxidan - Generic Name: Shenxidan - Dosage Form: Pills (Water Pills) - Approval Notification Number: 2025B03811 - Application Content: Changes to safety information in the drug instructions [4][12]. - Market Sales: No sales recorded for Baiyunshan in 2024 [13]. 4. Yiganling Tablets - Generic Name: Yiganling Tablets - Dosage Form: Tablets - Specification: Each tablet contains 38.5mg of Silybin - Approval Notification Number: 2025B04192 - Application Content: Changes to safety information in the drug instructions [5][14]. - Market Sales: In 2024, the domestic sales amounted to RMB 13.71 million, with no sales recorded for Baiyunshan [15]. 5. Maian Granules - Generic Name: Maian Granules - Dosage Form: Granules - Specification: Each bag contains 20g - Approval Notification Number: 2025B04164 - Application Content: Changes to safety information in the drug instructions [7][16]. - Market Sales: In 2024, the domestic sales amounted to RMB 9.28 million, with no sales recorded for Baiyunshan [16]. Company Impact - The approval of supplementary applications for the drugs is expected to enhance their safety and effectiveness, thereby improving the market competitiveness of the products. However, the approval is not expected to have a significant impact on the company's current performance [17].

Core Viewpoint - Recently, the company’s subsidiary, Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. Baiyunshan Pharmaceutical Factory, received the "Drug Supplement Application Approval Notice" from the National Medical Products Administration, enhancing the safety information of several products [1] Group 1 - The approved products include Abukuan Tablets, Kunling Pills, Shenxidan, Yiganling Tablets, and Maian Granules, which will improve the safety, effectiveness, and rational use of these drugs [1] - The approval is expected to enhance the market competitiveness of the products [1] - The approval will not have a significant impact on the company's current performance [1]

Core Viewpoint - Recently, Baiyunshan Pharmaceutical Group Co., Ltd. received the "Drug Supplement Application Approval Notice" from the National Medical Products Administration, enhancing the safety information of several drugs and improving market competitiveness [1] Group 1 - Baiyunshan Pharmaceutical's total factory received approval for the following drugs: Abdominal Ankang Tablets, Kunling Pills, Shenxi Dan, Yiganling Tablets, and Mai'an Granules [1] - The approval aims to improve the safety, effectiveness, and rational use of the mentioned drugs [1] - The approval is not expected to have a significant impact on the company's current performance [1]

Core Viewpoint - Recently, the company announced that its subsidiary, Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd., received the "Drug Supplement Application Approval Notice" from the National Medical Products Administration, enhancing the safety and effectiveness information of several drugs [1] Group 1 - The company obtained approval for the following drugs: Abukuan Tablets, Kunling Pills, Shenxidan, Yiganling Tablets, and Maian Granules [1] - The approval is expected to improve the safety, effectiveness, and rational use of these drugs, thereby enhancing their market competitiveness [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出的。 茲刊載廣州白雲山醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(www.sse.com.cn)刊登的 本公司關於分公司獲得藥品補充申請批件的公告之中文全文，僅供參考。 廣州白雲山醫藥集團股份有限公司 董事會 中國廣州，2025年9月16日 於本公告日，本公司董事會成員包括執行董事李小軍先生、程寧女士、程洪進先生、唐和平先生與 黎洪先生，及獨立非執行董事陳亞進先生、黃民先生、黃龍德先生與孫寶清女士。 证券代码：600332 证券简称：白云山 公告编号：2025－071 广州白云山医药集团股份有限公司 关于分公司获得药品补充申请批件的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对 其内容的真实性、准确性和完整性承担法律责任。 近日，广州白云山医药集团股份有限公司（以下简 ...